These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 21146821)

  • 1. Chromosome 9p21 and coronary risk--the mystery continues.
    Linsel-Nitschke P; Schunkert H
    Atherosclerosis; 2011 Feb; 214(2):257-8. PubMed ID: 21146821
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of Chr9p21 genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in human atherosclerotic plaque.
    Holdt LM; Sass K; Gäbel G; Bergert H; Thiery J; Teupser D
    Atherosclerosis; 2011 Feb; 214(2):264-70. PubMed ID: 20637465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome 9p21 and coronary artery disease.
    McPherson R
    N Engl J Med; 2010 May; 362(18):1736-7. PubMed ID: 20445187
    [No Abstract]   [Full Text] [Related]  

  • 4. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-γ activates expression of p15 and p16 regardless of 9p21.3 coronary artery disease risk genotype.
    Almontashiri NA; Fan M; Cheng BL; Chen HH; Roberts R; Stewart AF
    J Am Coll Cardiol; 2013 Jan; 61(2):143-7. PubMed ID: 23199516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosome 9p21 and cardiovascular disease: the story unfolds.
    Samani NJ; Schunkert H
    Circ Cardiovasc Genet; 2008 Dec; 1(2):81-4. PubMed ID: 20031549
    [No Abstract]   [Full Text] [Related]  

  • 7. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma.
    Conway C; Beswick S; Elliott F; Chang YM; Randerson-Moor J; Harland M; Affleck P; Marsden J; Sanders DS; Boon A; Knowles MA; Bishop DT; Newton-Bishop JA
    Genes Chromosomes Cancer; 2010 May; 49(5):425-38. PubMed ID: 20140953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer.
    Schmid M; Sen M; Rosenbach MD; Carrera CJ; Friedman H; Carson DA
    Oncogene; 2000 Nov; 19(50):5747-54. PubMed ID: 11126361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ANRIL: molecular mechanisms and implications in human health.
    Congrains A; Kamide K; Ohishi M; Rakugi H
    Int J Mol Sci; 2013 Jan; 14(1):1278-92. PubMed ID: 23306151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
    Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G
    Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke-related cholangiocarcinoma.
    Chinnasri P; Pairojkul C; Jearanaikoon P; Sripa B; Bhudhisawasdi V; Tantimavanich S; Limpaiboon T
    Hum Pathol; 2009 Jun; 40(6):817-26. PubMed ID: 19200577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resequencing and clinical associations of the 9p21.3 region: a comprehensive investigation in the Framingham heart study.
    Johnson AD; Hwang SJ; Voorman A; Morrison A; Peloso GM; Hsu YH; Thanassoulis G; Newton-Cheh C; Rogers IS; Hoffmann U; Freedman JE; Fox CS; Psaty BM; Boerwinkle E; Cupples LA; O'Donnell CJ
    Circulation; 2013 Feb; 127(7):799-810. PubMed ID: 23315372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
    Laud K; Marian C; Avril MF; Barrois M; Chompret A; Goldstein AM; Tucker MA; Clark PA; Peters G; Chaudru V; Demenais F; Spatz A; Smith MW; Lenoir GM; Bressac-de Paillerets B;
    J Med Genet; 2006 Jan; 43(1):39-47. PubMed ID: 15937071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs?
    Hannou SA; Wouters K; Paumelle R; Staels B
    Trends Endocrinol Metab; 2015 Apr; 26(4):176-84. PubMed ID: 25744911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor suppression for ARFicionados: the relative contributions of p16INK4a and p14ARF in melanoma.
    Peters G
    J Natl Cancer Inst; 2008 Jun; 100(11):757-9. PubMed ID: 18505965
    [No Abstract]   [Full Text] [Related]  

  • 16. 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response.
    Harismendy O; Notani D; Song X; Rahim NG; Tanasa B; Heintzman N; Ren B; Fu XD; Topol EJ; Rosenfeld MG; Frazer KA
    Nature; 2011 Feb; 470(7333):264-8. PubMed ID: 21307941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia.
    Bertin R; Acquaviva C; Mirebeau D; Guidal-Giroux C; Vilmer E; Cavé H
    Genes Chromosomes Cancer; 2003 May; 37(1):44-57. PubMed ID: 12661005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.
    García-Castellano JM; Villanueva A; Healey JH; Sowers R; Cordon-Cardo C; Huvos A; Bertino JR; Meyers P; Gorlick R
    Clin Cancer Res; 2002 Mar; 8(3):782-7. PubMed ID: 11895909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations.
    Perrone F; Tamborini E; Dagrada GP; Colombo F; Bonadiman L; Albertini V; Lagonigro MS; Gabanti E; Caramuta S; Greco A; Torre GD; Gronchi A; Pierotti MA; Pilotti S
    Cancer; 2005 Jul; 104(1):159-69. PubMed ID: 15929122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
    Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
    Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.